Shandong Kaisheng New Materials (SZ:301069) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-07-23 23:19Core Viewpoint - The article discusses the equity change involving Huabang Life Health Co., Ltd. and Shandong Kaisheng New Materials Co., Ltd., highlighting a passive dilution and inquiry transfer of shares, which will not affect the control or governance structure of the company [3][12]. Group 1: Equity Change Details - The equity change involves Huabang Life Health Co., Ltd. reducing its stake in Shandong Kaisheng New Materials from 44.51% to 39.75% through a transfer of 20,000,000 shares at a price of 13.69 yuan per share, totaling 273,800,000 yuan [3][4][10]. - The transfer was conducted as a non-public inquiry transfer and does not trigger a mandatory tender offer [3][12]. - The inquiry transfer was completed on July 22, 2025, and the shares transferred represent 4.75% of the total share capital of the company [4][5]. Group 2: Transfer Process and Participants - The inquiry transfer was organized by CITIC Securities, which facilitated the process and ensured compliance with relevant regulations [4][11]. - A total of 13 institutional investors participated in the inquiry transfer, none of whom held shares prior to the transfer [7][10]. - The inquiry process involved sending invitations to 418 institutional investors, with 16 valid bids received during the specified time frame [8][10]. Group 3: Regulatory Compliance - The transfer process adhered to the principles of fairness and compliance with the current securities market regulations [11][12]. - The company will continue to fulfill its disclosure obligations and comply with relevant laws and regulations regarding shareholder equity changes [15].